Article
CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Clinical and experimental pharmacology & physiology - 1 Nov 2014
Pedersen Rasmus Steen, Nielsen Flemming, Stage Tore Bjerregaard, Vinholt Pernille Just, el Achwah Alaa Bilal, Damkier Per, Brosen Kim
Abstract excerpt
The aim of the present study was to determine the impact of CYP2C19*17 on the pharmacokinetics and pharmacodynamics of the active metabolite of clopidogrel and the pharmacokinetics of proguanil. Thus, we conducted an open-label two-phase cross-over study in 31 healthy male volunteers (11 CYP2C19*1/*1, 11 CYP2C19*1/*17 and nine CYP2C19*17/*17). In Phase A, the pharmacokinetics of the derivatized active metabolite...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.